Unidentified Analyst: Okay.
Erez Israeli: Market share we are doing good.
Unidentified Analyst: Okay. So, my other question is on ?
Erez Israeli: ?
Unidentified Analyst: Yes.
Operator: Sorry to interrupt you. Sumit, may I request to speak with the handset please, your voice is not coming clear.
Unidentified Analyst: Okay. I will turn back in queue.
Operator: Thank you. Next question is from the line of Prakash Agarwal from Axis Capital. Please go ahead.
Prakash Agarwal: Yes, just a quick follow-up just trying to understand the smaller strengths where we had exclusivity, when is the competition expected to come for REVLIMID?
Parag Agarwal: The voice is breaking up. Something is wrong with the line. We can’t hear you well.
Erez Israeli: Can you repeat the question please?
Prakash Agarwal: Sure sir. Am I audible now?
Erez Israeli: Yes, please.
Prakash Agarwal: Yes, I’m just trying to understand when are we expecting competition on the smallest trends for REVLIMID, where we have exclusivity?
Erez Israeli: We have exclusivity for 180 days. So, therefore, it’s a 181 probably it will come.
Prakash Agarwal: Okay. And would that be decent — a meaningful contributor to the run rate — whatever run rate we are doing on REVLIMID sales? Or these are the small shares?
Richa Periwal: Your voice is breaking; could we just repeat the question again please?
Prakash Agarwal: I’m asking would that be meaningful contribution the overall sales, REVLIMID or US sales or is it just small share?
Erez Israeli: A cannot share the information that SKU. Like I mentioned before, indeed exclusivity will go in that period of time and the for that will continue to be meaningful to us. Sorry that I cannot share, I understand.
Prakash Agarwal: Sure. No, if you can repeat what you said, it will continue to grow?
Erez Israeli: It will continue to be meaningful for , that’s what I said.
Prakash Agarwal: Okay, lovely. Thank you so much.
Operator: Thank you. Next question is from the line of Rahul from IIFL Securities. Please go ahead.
Rahul Singh: Yes. Hi. Sir, can you provide an update to with respect to some of these complex US generic assets, which you had disclosed during your analyst meet last year. So, when do we expect launches for these complex assets to begin for us in the US market? Given one of your peers recently indicated that market formation has begun for a product regarding ?
Parag Agarwal: Yes, Rahul, so, we also have approval of this product. So, I think it is linked to the IP. So, as it allows us, we have a settlement also with the innovator. So, as per the settlement terms, we will be able to launch.
Erez Israeli: And for your border questions, we are very much on track of what we share then also we are planning to launch complex products that was not shared on the investor meeting. So, the pipeline of complex product is robust and getting better.
Rahul Singh: Sure sir. So, any timelines which you can share in terms of products like Octreotide or liraglutide or teriparatide, when do you expect these launches to begin? So, would these launches be over the next 12 to 18-month period or beyond that?
